What the FDA labels say about taking them together
Fluconazole and meloxicam
Fluconazole's FDA label (Fluconazole) of April 2, 2026 names meloxicam in its drug interactions section, and meloxicam's label names fluconazole too. The meloxicam label: “In vitro studies indicate that CYP2C9 plays an important role in this metabolic pathway with a minor contribution of the CYP3A4 isozyme. …”
Check it at the source: the fluconazole FDA label on DailyMed (effective April 7, 2026, Zydus Pharmaceuticals (USA) Inc.); the meloxicam FDA label on DailyMed (effective January 29, 2026, PD-Rx Pharmaceuticals, Inc.).
What does the fluconazole label say about meloxicam?
Fluconazole label (Mylan Pharmaceuticals Inc., April 2, 2026), drug interactionsAlthough not specifically studied, fluconazole has the potential to increase the systemic exposure of other non-steroidal anti-inflammatory drugs (NSAIDs) that are metabolized by CYP2C9 (e.g., naproxen, lornoxicam, meloxicam, diclofenac).
Source: FDA drug label (Fluconazole, NDA020090), Mylan Pharmaceuticals Inc., effective April 2, 2026 (SPL set 737e0fac-a2d2-4053-a0d7-edbfb6248f69), via openFDA
Source: FDA drug label (fluconazole), Zydus Pharmaceuticals (USA) Inc., effective April 7, 2026 (SPL set d1364455-1537-46d4-b093-38cca3be778f), via openFDA; the full label on DailyMed
What does the meloxicam label say about fluconazole?
Qamzova label (Nanjing Delova Biotech Co., Ltd., July 16, 2026), drug interactionsCYP2C9 Inhibitors Clinical Impact: In vitro studies indicate that CYP2C9 (…) plays an important role in this metabolic pathway with a minor contribution of the CYP3A4 isozyme. Thus concomitant usage of CYP2C9 inhibitors (…) may lead to abnormally high plasma levels of meloxicam due to reduced metabolic clearance [ see Use in Specific Populations (); … Intervention: Consider dose reduction in patients undergoing treatment with CYP2C9 inhibitors, and monitor patients for adverse effects.
Source: FDA drug label (Qamzova, NDA217593), Nanjing Delova Biotech Co., Ltd., effective July 16, 2026 (SPL set 385fd779-1be1-49ae-8213-750b96ecc997), via openFDA
Source: FDA drug label (MELOXICAM), PD-Rx Pharmaceuticals, Inc., effective January 29, 2026 (SPL set 19c13159-71f1-2427-e063-6394a90ad44e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Fluconazole | Meloxicam | |
|---|---|---|
| Labeled for | Fungal infections, Urinary tract infections | Osteoarthritis, Rheumatoid arthritis, Pain |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.380 per tablet 200 mg tablet | $0.0166 per tablet 7.5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once